LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis

LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis

Abstract Background Cisplatin (DDP) is a major chemotherapeutic drug which was widely used for cervical cancer (CC) patients with advanced or recurrent although its limitation in the development of resistance. LncRNA nicotinamide nucleotide transhydrogenase-antisense RNA1 (NNT-AS1) has been reported...

Full description

Bibliographic Details
Main Authors: Yanjie Liu, Ruixia Guo, Yuhuan Qiao, Liping Han, Mingzhu Liu
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Cancer Cell International
Subjects:
NNT-AS1
miR-186
HMGB1
Cisplatin resistance
Cervical cancer
Online Access:http://link.springer.com/article/10.1186/s12935-020-01278-9

Internet

http://link.springer.com/article/10.1186/s12935-020-01278-9

Similar Items